国产头孢哌酮/舒巴坦钠治疗老年下呼吸道细菌性感染的临床疗效评价  

Clincial effect of domestic sulbactam/cefoperazone in treating senile lower respiratory tract bacterial infection.

作　　者：陈燕启[1] 冷斌[1] 周浩[1] 王旭涛[1] 乔延东[1] 姜宏志[1] 

机构地区：[1]卫生部北京医院呼吸科,北京100730

出　　处：《中国综合临床》2004年第10期869-870,共2页Clinical Medicine of China

摘　　要：目的　评价国产头孢哌酮 /舒巴坦钠治疗老年下呼吸道细菌性感染的临床疗效。方法　中、重度感染患者 6 0例随机分为观察组和对照组 ,各 30例。观察组应用国产头孢哌酮 /舒巴坦钠治疗 ,对照组使用头孢哌酮钠治疗。结果观察组和对照组临床有效率分别为 93.3%、90 .0 % ;细菌转阴率 92 .6 %、88.5 % ;产酶菌转阴率 89.5 %、82 .4 % ;细菌清除率 85 .2 %、80 .8% ;细菌敏感率 94 .3%、90 .6 % ;不良反应发生率 6 .6 7%、3.33% (P >0 .0 5 )。两组效价比分别为 (0 .39± 0 .2 9)与 (0 .19± 0 .11) (P <0 .0 5 )。结论　国产头孢哌酮 /舒巴坦钠效价比较高 ,临床试验结果满意 ,适于治疗中、重度老年下呼吸道细菌性感染 ,并有利于降低整体医疗费用成本。Objective To evaluate the efficacy-price of sulbactam/cefoperazone in the treatment of bacterial infections of senile lower respiratory tract.Methods 60 senile patients with lower respiratory tract infections were randomly divided into control group and trial group(n=30,each group).Sulbactam/ cefoperazone were taken as trial groups and cefoperazone was taken as control medicine.Results The clinical efficacy rates in two groups were 93.3% and 90.0%,the negative rates of bacteria in two groups were 92.6% and 88.5%,the negative rates of producing B-lactamase bacterial were 89.5% and 82.4%,the bacteriological eradication rates were 85.2% and 80.8%,the sensitivity rates of bacteria were 94.3% and 90.6%,and the adverse drug reaction of the two groups were 6.67% and 3.33%(P>0.05),respectively.The ratio of efficacy-price of them were(0.39±0.29)and (0.19±0.11)(P<0.05).Conclusion Sulbactam/Cefoperazone is of a high efficacy-price ratio in the treatment of moderate to severe elderly bacterial infections of lower respiratory tract,which can help to lower the cost.

关 键 词：头孢哌酮 舒巴坦钠 老年人 细菌性感染 

分 类 号：R56[医药卫生—呼吸系统]